Biolife Solutions (BLFS) EBITDA Margin (2010 - 2026)

Biolife Solutions (BLFS) has 17 years of EBITDA Margin data on file, last reported at 0.1% in Q1 2026.

• On a quarterly basis, EBITDA Margin rose 236.0% year-over-year to 0.1% in Q1 2026; TTM through Mar 2026 was 15.39%, a 1325.0% decrease from a year earlier, with the FY2025 full-year figure at 17.26%, down 1126.0% from the prior year.
• EBITDA Margin for Q1 2026 stood at 0.1%, down from 7.17% in the prior quarter.
• Over the last five years, EBITDA Margin for BLFS reached as high as 7.17% in Q4 2025 and fell as low as 218.96% in Q4 2022.
• Historically, EBITDA Margin has averaged 47.4% across 5 years, with a median of 22.0% in 2022.
• Across the five-year window, EBITDA Margin tumbled 17429 bps in 2022 and soared 15254 bps in 2023, its largest moves.
• Year by year, EBITDA Margin stood at 218.96% in 2022, then jumped by 43 bps to 125.43% in 2023, then surged by 103 bps to 3.59% in 2024, then surged by 100 bps to 7.17% in 2025, then plunged by 99 bps to 0.1% in 2026.
• Per Business Quant data, the three most recent EBITDA Margin figures were 0.1% in Q1 2026, 7.17% in Q4 2025, and 0.32% in Q3 2025.